Omnicell (OMCL): Exploring Valuation After Recent Share Weakness and Ongoing Business Transition

Simply Wall St.

Oct 13

Omnicell (OMCL) shares have been under pressure lately, retreating 4% in the last day and down 7% over the past month. The healthcare technology company’s recent stock movement may pique investor ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575429283"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575429283\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575429283?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","is_english":true,"pubTime":"2025-10-13 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575429283","market":"hk","top_or_hot":-1,"title":"Omnicell (OMCL): Exploring Valuation After Recent Share Weakness and Ongoing Business Transition","media":"Simply Wall St.","content":"<div>\n<p>Omnicell (OMCL) shares have been under pressure lately, retreating 4% in the last day and down 7% over the past month. The healthcare technology company’s recent stock movement may pique investor ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/omnicell-omcl-exploring-valuation-after-recent-share-weaknes\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omnicell (OMCL): Exploring Valuation After Recent Share Weakness and Ongoing Business Transition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmnicell (OMCL): Exploring Valuation After Recent Share Weakness and Ongoing Business Transition\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-13 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/omnicell-omcl-exploring-valuation-after-recent-share-weaknes><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Omnicell (OMCL) shares have been under pressure lately, retreating 4% in the last day and down 7% over the past month. The healthcare technology company’s recent stock movement may pique investor ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/omnicell-omcl-exploring-valuation-after-recent-share-weaknes\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMCL","symbol_name":"Omnicell","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/omnicell-omcl-exploring-valuation-after-recent-share-weaknes","article_id":"2575429283","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell/news/omnicell-omcl-exploring-valuation-after-recent-share-weaknes","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2575429283","pubTimestamp":1760364964,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Omnicell (OMCL) shares have been under pressure lately, retreating 4% in the last day and down 7% over the past month. The healthcare technology company’s recent stock movement may pique investor curiosity, as shares are lagging behind longer-term benchmarks.\nSee our latest analysis for Omnicell.\nAfter a difficult year for Omnicell, with a year-to-date share price return of -32.94% and a 1-year total shareholder return of -30.45%, momentum remains weak despite a brief 90-day rebound. The...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMCL":"Omnicell","BK4082":"医疗保健设备","BK4167":"医疗保健技术"},"translate_title":"Omnicell(OMCL)：在近期股价疲软和持续的业务转型后探索估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMCL":1.5},"content_text":"Omnicell (OMCL) shares have been under pressure lately, retreating 4% in the last day and down 7% over the past month. The healthcare technology company’s recent stock movement may pique investor curiosity, as shares are lagging behind longer-term benchmarks. See our latest analysis for Omnicell. After a difficult year for Omnicell, with a year-to-date share price return of -32.94% and a 1-year total shareholder return of -30.45%, momentum remains weak despite a brief 90-day rebound. The volatile moves suggest shifting investor sentiment and possible reevaluation of the company's growth outlook and risk profile. With healthcare stocks making headlines for innovation and resilience, it’s a smart time to see who else is standing out. Check out the latest opportunities in our See the full list for free.. With shares trading below analyst price targets and recent gains failing to reverse longer-term declines, the big question remains: is Omnicell now trading at a bargain, or is the market already pricing in modest growth ahead? AdvertisementMost Popular Narrative: 32.5% Undervalued Omnicell’s latest close of $29.72 sits notably below the most widely followed fair value estimate of $44, suggesting significant upside if the narrative projections hold. As the market weighs Omnicell’s recurring revenue transition, automation leadership, and cloud focus, the most popular narrative offers a bullish perspective that is drawing attention.  “The continued rollout and adoption of the cloud-native OmniSphere platform across Omnicell's customer base will simplify enterprise-wide medication management, make adding new features and integrating advanced analytics much easier, and accelerate the company's transition to higher-margin, recurring SaaS-based revenues, supporting improved revenue predictability and net margins.”  Read the complete narrative. Curious what powers this bullish target? The secret sauce behind the high fair value is a bold revenue and profit turnaround, paired with a future earnings multiple rarely seen outside tech. Want the full blueprint and the one assumption that makes or breaks this upside? Dive in to see the drivers no one is talking about. Result: Fair Value of $44 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, factors such as ongoing tariff impacts and slow progress in recurring revenues could challenge Omnicell’s positive outlook and growth trajectory in the years ahead. Find out about the key risks to this Omnicell narrative. Another View: Market Ratios Raise Questions Taking a look through the lens of market ratios, Omnicell appears pricey. Its current valuation is nearly double the average for both the industry and its peers, and it also stands far above the fair ratio the market could move toward. This sizable gap means the shares could be exposed to additional downside risk if sentiment turns, or it might simply signal high future growth expectations. Is the market overconfident, or is there something more beneath the surface? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:OMCL PE Ratio as at Oct 2025 Build Your Own Omnicell Narrative If you see things differently or want to dig deeper into the numbers yourself, you can craft your own view in just a few minutes, so why not Do it your way. A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Omnicell. Looking for more investment ideas? Seize the chance to uncover what others might miss by checking out unique stock picks tailored to different strategies. Don't let winning opportunities pass you by. Expand your investing universe using these tools:  Target steady income streams by starting with these 19 dividend stocks with yields > 3% featuring reliable payers with yields exceeding 3%. Capitalize on powerful market trends by tapping into innovation with these 24 AI penny stocks and spot the companies driving the AI revolution forward. Catch mispriced gems by seeing these 891 undervalued stocks based on cash flows offering value boosts based on robust cash flow fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}